Ricardo Gazzinelli to Adjuvants, Immunologic
This is a "connection" page, showing publications Ricardo Gazzinelli has written about Adjuvants, Immunologic.
Connection Strength
0.364
-
Grimaldi G, Teva A, Porrozzi R, Pinto MA, Marchevsky RS, Rocha MG, Dutra MS, Bru?a-Romero O, Fernandes AP, Gazzinelli RT. Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen. PLoS Negl Trop Dis. 2014 Jun; 8(6):e2853.
Score: 0.102
-
Junqueira C, Guerrero AT, Galv?o-Filho B, Andrade WA, Salgado AP, Cunha TM, Ropert C, Campos MA, Penido ML, Mendon?a-Previato L, Previato JO, Ritter G, Cunha FQ, Gazzinelli RT. Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLoS One. 2012; 7(5):e36245.
Score: 0.088
-
Machado AV, Caetano BC, Barbosa RP, Salgado AP, Rabelo RH, Garcia CC, Bruna-Romero O, Escriou N, Gazzinelli RT. Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity. Vaccine. 2010 Apr 19; 28(18):3247-56.
Score: 0.076
-
Marques RF, Gimenez AM, Caballero O, Simpson A, Salazar AM, Amino R, Godin S, Gazzinelli RT, Soares IS. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol?) as adjuvant. Vaccine. 2024 Apr 02; 42(9):2394-2406.
Score: 0.050
-
Dias Assis BR, Gomes IP, de Castro JT, Rivelli GG, de Castro NS, Gomez-Mendoza DP, Bagno FF, Hojo-Souza NS, Chaves Maia AL, Lages EB, da Fonseca FG, Ribeiro Teixeira SM, Fernandes AP, Gazzinelli RT, Castro Goulart GA. Quality attributes of CTVad1, a nanoemulsified adjuvant for phase I clinical trial of SpiN COVID-19 vaccine. Nanomedicine (Lond). 2023 08; 18(18):1175-1194.
Score: 0.048